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compliance-sensitive. CONCLUSIONS: Adhering to GOLD guidelines, apart from 
having patients treated appropriately, National/Regional Healthcare Systems could 
save signiﬁ cant resources and re-allocate them in more rational manner.
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EFFECTIVENESS AND EFFICIENCY OF ME-TOO LISTS AS ILLUSTRATED 
BY THE EXAMPLE OF INTRANASAL STEROIDS
Schoeffski O1, Becker B2
1University Erlangen-Nuernberg, Nuernberg, Germany; 2Essex Pharma, Munich, Germany
OBJECTIVES: A me-too list has been implemented in a German KV (regional associa-
tion of SHI-accredited physicians) with the intention of promoting cost-effective 
prescribing behavior. The aim was to investigate whether the me-too list is an effective 
steering tool. a mometasone-containing nasal spray (MHN) which has been listed as 
a me-too, should be substituted by budesonide-containing nasal sprays (BHN), 
because MHN therapy is assumed to be equally effective but more cost intensive than 
BHN. MHN’s market share has declined after listing. METHODS: A retrospective 
study of anonymized patient data was conducted from March to April 2009 in KV 
North Rhine. ENT physicians documented patients which had received MHN for 
minimum 12 months and who had then been switched to another intranasal steroid 
(INS). Evaluation was done with descriptive statistics. RESULTS: A total of 676 
patients documented by 76 physicians were eligible for the analysis. a total of 189 
patients (28%) received MHN only; a switch to other INS was documented for 487 
patients (72%). ENTs cited economic reasons for changing the INS in 86.4% of the 
cases. Compared to other INS, the average number of consultations for MHN treat-
ment and the administered dose of MHN, regardless of diagnosis, were lower, MHN 
patients required reﬁ ll prescriptions later, less co medication, and MHN generated 
lower daily treatment costs in real-life. CONCLUSIONS: Reasons for switching from 
MHN were economically. Therefore the me-too list has a heavy impact on prescription 
behavior. Daily treatment costs of MHN were lower in real-life. Analysis based on 
PDD (prescribed daily doses) showed that the economic effect of switching a patient 
to another INS was far less than expected. For instance it was offset by a higher 
number of consultations in association with the cheaper alternatives in more frequent 
use. An economic evaluation with a precise quantiﬁ cation would be of major interest 
in future.
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OPTIMIZATION OF GUIDELINES’ SUSTAINABILITY BY EVALUATING 
FACTORS PREDICTING TREATMENT RESPONSE IN PATIENTS WITH 
ALLERGIC RHINITIS
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OBJECTIVES: To assess predictive factors and risk proﬁ les for treatment response in 
patients with allergic rhinitis. It was the aim to create a platform giving support to 
the development of interventions optimizing the daily use as well as the sustainability 
of the existing national and international guidelines and therewith minimizing the 
progression to severe chronic upper airway diseases. METHODS: For this purpose, 
76,981 case reports of patients with allergic rhinitis from ten post-marketing-studies 
in Germany were aggregated by the use of an IPD meta-analysis. The data pool was 
examined in terms of signiﬁ cant predictive factors by univariat methods, logistic 
regression and discriminant analysis. The predictive ability of the model was assessed 
by a 10 fold crossvalidation. RESULTS: First, we investigated the data pool as a 
whole, and the results showed that 20.6% of the patients did not respond to their 
therapy. Especially patients who were treated according to current guidelines had a 
higher risk of non-response (28% vs. 19.3%). Next, we examined the data pool in 
terms of signiﬁ cant predictive factors resulting in non-response of patients receiving 
an adequate guideline-conform therapy. The primary baseline determinants were a 
positive history of allergy in the family, duration and severity of disease, the periodicity 
of an allergen (perennial allergens) and concomitant diseases. Especially patients with 
asthma as well as patients suffering from more than one concomitant disease had a 
higher risk of non-response (32.4% and 34%). The main follow up determinants were 
patient’s compliance, safety and the treatment process. a total of 63.4% of patients 
with a poor compliance, which was enforced by an inadequate safety were non-
responder. CONCLUSIONS: These results support the ﬁ ndings of current clinical 
trials describing a non-responder rate of about 20% and encourage efforts to optimize 
guidelines as well as to achieve a sustainability of guidelines. 
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ADJUSTING FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
(COPD) SEVERITY IN DATABASE RESEARCH: FEASIBILITY OF 
DEVELOPING AND VALIDATING AN ALGORITHM
Goossens LM1, Baker CL2, Monz BU3, Zou KH2, Rutten-van Mölken MP1
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OBJECTIVES: When comparing interventions through routine database research, it 
is important to adjust for COPD severity. GOLD guidelines grade COPD severity 
according to lung function (FEV1% predicted). Most databases lack data on lung 
function. Previous database research has approximated COPD severity using demo-
graphics and health care utilization. This study aims to derive an algorithm for COPD 
severity using baseline data from a large, respiratory trial (UPLIFT). METHODS: 
Several partial proportional odds logit models were used to estimate the probabilities 
of being in GOLD stages II, III and IV. The predicted GOLD stage for each patient 
was deﬁ ned as the state with the highest predicted probability. The concordance 
between the predicted and the observed (according to lung function) stage was assessed 
with κ-statistics. Models were estimated in a random selection of 2/3 of all patients 
enrolled in Western Europe (n = 2439) and validated in the remaining patients (n = 
1259). The ﬁ nal model was re-estimated in a subsample with a balanced distribution 
across severity stages. RESULTS: In the validation set, 47% were in stage II, 44% in 
III, and 9% in IV. In the ﬁ nal model, a higher risk of more severe COPD was associ-
ated with being male, younger, lower BMI, and certain medications (long-acting and 
short-acting bronchodilators, leukotriene modiﬁ ers, oral steroids), oxygen and having 
quit smoking. No relationship was found between severity and co-morbidities, previ-
ous health care resource use (e.g. emergency room, hospitalizations) and inhaled 
corticosteroids, xanthines, or mucolytics. The concordance between observed and 
predicted disease states was generally poor (κ = 0.15) and only slightly better in the 
balanced sample (κ = 0.22). CONCLUSIONS: Data from a well controlled trial setting 
indicated that COPD severity cannot be reliably predicted from demographics and 
health care use. This limitation should be considered when interpreting ﬁ ndings from 
database studies, and additional research should explore other methods allowing to 
account for COPD severity.
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USE OF PROPENSITY SCORE MATCHING, STANDARD REGRESSION 
ANALYSIS AND INSTRUMENTAL VARIABLE METHOD IN OUTCOMES 
RESEARCH STUDIES: A COMPARATIVE ANALYSIS
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OBJECTIVES: Propensity score matching and standard regression analysis are 
common ways to control for baseline differences between comparative groups. They 
control for observable factors. Instrumental variable approach controls not only for 
observable factors but also unobservable factors. We compared the three methods and 
showed that using more advanced techniques alters the estimated results in a signiﬁ -
cant way. METHODS: Using data from U.S. claims databases, the effect of treatment 
on total health care expenditures among asthma patients was estimated. Reimburse-
ment amounts were dollars paid by the health plan to the provider including patient 
co-payments and deductibles. Doctors’ prescribing patterns were used as an instru-
mental variable for treatment choice. Propensity score matching was employed using 
the nearest neighbor matching algorithm. Generalized linear model was used as an 
alternative risk adjustment technique. RESULTS: Patients treated with control medica-
tion were younger, more likely to live in the northeast and south of the United States 
and have a higher Charlson comorbidity score, Elixhauser score and chronic disease 
score relative to patients treated with reliever medication. The difference between one 
year health care costs for reliever and controller medication was $2,345 by propensity 
score matching, $2,195 by generalized linear model, and $2,997 by instrumental 
variable approach. The difference was statistically signiﬁ cant. CONCLUSIONS: After 
adjusting for patient clinical and demographic characteristics, controller medication 
was less costly than reliever medication. The choice of risk adjustment was important. 
The technique that controlled for both observed and unobserved biases (instrumental 
variable technique) provided a difference of almost 30% higher than the other 
techniques.
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DIFFERENCES: OLS, GAMMA, AND QUANTILE REGRESSION
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OBJECTIVES: Estimation of cost differences between groups has been assessed using 
a variety of econometric techniques. Recent literature commonly uses ordinary least 
squares (OLS) with log transformed costs or generalized linear models with a log link 
function and gamma error distribution; however recommendations from the ﬁ eld of 
econometrics suggest that quantile regression models may provide more informative 
comparisons of health care cost data. The objective of this study was to compare three 
econometric models for estimating health care cost differences. METHODS: The 
econometric models were compared using a cross-sectional sample of patients hospital-
ized during 2007 for COPD exacerbations from Premier’s Perspective Comparative 
Database, a population-based U.S. inpatient database. Admissions were classiﬁ ed into 
two groups according to the presence of pneumonia. Total inpatient cost was regressed 
on pneumonia status and confounders using: 1) OLS with log-transformed costs; 2) 
generalized linear models with log link and gamma error; and 3) quantile regression 
with comparisons at every 5th percentile. Cost differences were calculated by subtract-
ing model based estimated costs between COPD patients with and without pneumo-
nia. RESULTS: There were 69,841 COPD exacerbation admissions. Of these, 69,286 
admissions had nonzero costs, and 6,840 (9.9%) had evidence of pneumonia. In the 
OLS model, estimated costs were $3,949 (95%CI: $3,822–$4,076) higher in patients 
with pneumonia; in the log-gamma model, the estimated costs were $4,442 (95%CI: 
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$4,297–$4,587) higher; while the median quantile difference was $3,756 (95%CI: 
$3,636–$3,876). The quantile regression differences ranged from a low of $2,078 
(95%CI: $2,012–$2,145) for the 5th quantile to a high of $8,691 (95%CI: $8,395–
$8,987) for the 95th quantile. CONCLUSIONS: Results from econometric regression 
models can vary greatly depending on model assumptions. Quantile regression results 
provide a detailed picture of cost differences across the entire cost distribution, illus-
trating important non-uniformities of differences between groups.
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TESTING THE USABILITY AND LANGUAGE OF E-PRO TRANSLATIONS 
DURING LINGUISTIC VALIDATION: COGNITIVE DEBRIEFING ON 
E-DEVICE VS. PRINT OUTSCREENSHOTS
Grataloup G1, Fernandez N1, Dale P2, Muehlhausen W3
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OBJECTIVES: Electronic data collection is a prominent evolution in the Patient-
Reported Outcomes (PRO) ﬁ eld. Developing translations for e-formats must involve 
a rigorous methodology ensuring conceptual equivalence and cultural relevance across 
languages. Ideally comprehension and acceptability of translations should be tested 
using the actual e-device. For logistical reasons this may be challenging. Alternative 
methods include testing of translations using print outs of screenshots. The translation 
of an Asthma Diary into 20 languages was the opportunity to compare both methods. 
METHODS: (1) Identiﬁ cation of the languages using e-device testing versus those 
using screenshots; (2) comparison of the interview guides used for the respective testing 
methods; and (3) analysis and comparison of the results. RESULTS: A total of 15 
languages were tested on the e-device, 5 with screenshots. The interview guide used 
to test the e-device contained linguistic considerations and questions on instructions 
and use of the device. The interview guide for the screenshots was purely linguistic in 
nature, so as not to confuse respondents with questions about the hypothetical use of 
the e-device. In terms of linguistic observations no differences were seen between the 
e-device and the screenshot testing methods. Feedback on the device usability differed 
by country but also across regions. In most countries/languages observations were 
made around the size of the font/screens and the device instructions. CONCLUSION: 
Testing translations using the actual e-device not only provides comprehensive feed-
back on the language of the items, but also information on the practical use of the 
device, and the interaction of both in the context of each country. Screenshot testing 
can be considered an alternative in cases where e-device testing is difﬁ cult.
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EMPLOYING MULTI-ATTRIBUTE UTILITY THEORY TO DEVELOP THE 
EXACT-U: A PREFERENCE-BASED MEASURE FOR COPD 
EXACERBATION UTILITIES
Petrillo J1, Cairns J1, Revicki DA2
1London School of Hygiene and Tropical Medicine, London, UK; 2United BioSource 
Corporation, Bethesda, MD, USA
BACKGROUND: The EXACT (Exacerbations of COPD Tool) is a daily diary used 
in clinical trials to evaluate frequency, severity, and duration of COPD exacerbations. 
Reporting utilities from the EXACT allows a more accurate account of preference 
change for economic evaluations than current methods. Multi-attribute utility theory 
(MAUT) employs a series of equations to develop a function (MAUF) to report utili-
ties. OBJECTIVES: To develop and validate an MAUF to estimate utilities from the 
EXACT for use in UK cost-effectiveness studies. METHODS: EXACT-U is comprised 
of 5 items with 3–5 levels each. Items and levels were grouped to form mixed-level 
and corner health states. Development group was used for MAUF construction; sepa-
rate Validation group was used to test functions. UK general public respondents valued 
11 health states (including best/worst) using TTO from full health/dead over 10 years. 
MAUF used the multiplicative model by: (1)-Calculating mean utility of each attribute 
level; (2)- Calculating group disutilities for each level; (3)-Applying multiplicative 
model to derive disutility function; and (4)-Converting disutility function to utility 
function. Performance assessed by: number of inconsistencies predicted, mean absolute 
error (MAE), and root mean squared error (RMSE). Models validated using a second-
ary analysis of a separate data set of EXACT patient data to test discriminant validity 
(statistical signiﬁ cance) and responsiveness (standardized response mean (SRM)). 
RESULTS: TTO interviews conducted with 400 respondents: 350 Development 
group, 50 Validation group. Respondents were: 36 yrs old (13.5 SD), 39.2% male, 
and 46.4% White British. MAUF reported MAE = 0.032, and RMSE = 0.170. Dis-
criminant validity supported by utility differences by clinical severity: stable/acute (P 
= 0.001); mild/moderate (p = 0.01); moderate/severe (p = 0.0001); and severe/very 
severe (P = 0.14). Responsiveness by SRM was 0.52 (Day 3), 0.55 (Day 7), 0.66 (Day 
10), and 0.76 (Day 13). CONCLUSIONS: The EXACT-U is a condition-speciﬁ c 
preference-based measure to report COPD exacerbation utilities with minimal error, 
good discrimination, and good responsiveness.
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ADVANCED PATTERN RECOGNITION METHODS FOR PREDICTING 
TREATMENT RESPONSE IN PATIENTS SUFFERING FROM ALLERGIC 
RHINITIS
Krajewski J, Koeberlein J
University of Wuppertal, Wuppertal, Germany
OBJECTIVES: The aim of the present analysis was to optimize the prediction of 
treatment response in patients with allergic rhinitis. To determine an optimal predic-
tion accuracy, we used different Pattern Recognition (PR) approaches and evaluated 
their added value compared to standard predictive models as Logistic Regression, and 
Linear Discriminant Analysis. METHODS: In order to optimize the prediction of 
treatment response, 76,981 case reports of patient with allergic rhinitis from ten post-
marketing-studies in Germany were analyzed by means of PR methodology. The 
processing steps applied within this study are: (a) feature extraction (genetic algorithm 
based synthetic feature calculation), (b) dimensionality reduction (correlation ﬁ lter 
based feature selection, wrapper based feature selection, Principle Component Analy-
sis based feature transformation), (c) classiﬁ cation (Support Vector Machine, Decision 
Tree, K-Nearest Neighbor, Random Forest, Artiﬁ cial Neural Network, Bagging, 
Boosting Logistic Regression, Linear Discriminant Analysis), and (d) validation (leave-
one-sample-out cross validation). RESULTS: The AdaBoost Support Vector Machine 
classiﬁ er with correlation ﬁ lter based feature selection achieved the highest unweighted 
mean recall rate (mean of sensitivity and speciﬁ city; URR) of 62.8%. The standard 
Logistic Regression approach yielded 50.4% (−12.4%), the Linear Discriminant 
Analysis 50.6% (−12.6%). CONCLUSIONS: In comparison to standard learning 
schemes as e.g. Logistic Regression, and Linear Discriminant Analysis applying 
advanced PR methods improves substantially the prediction of treatment response in 
patients with allergic rhinitis. Due to the achieved added value and the superiority of 
Pattern Recognition methods within several benchmarking studies, advanced PR 
methods should be primarily considered for modeling and prediction tasks within the 
ﬁ eld of pharmacoeconomics. 
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PMC1
BEST PRACTICES IN REPORTING OF PROSPECTIVE OBSERVATIONAL 
STUDIES
Bharmal M, Viswanathan S, Gemmen E
Quintiles, Rockville, MD, USA
OBJECTIVES: Although a number of guidelines are available for the reporting of 
clinical trials and interventional studies, there is limited consensus in the structure, 
content and terminology associated with reporting of prospective non-interventional 
observational studies. The objective of this study was to describe best practices in 
reporting of observational studies based on a review of relevant guidelines for report-
ing data from clinical studies. METHODS: A systematic literature review was con-
ducted and six relevant guidelines that could be adapted for reporting of results from 
prospective non-interventional observational studies were identiﬁ ed. The guidelines 
reviewed included the FDA guideline for abbreviated clinical study reports (CSR), the 
EMEA guideline for CSR, the International Conference on Harmonization (ICH) E3 
guideline for CSR, Consolidated Standards of Reporting Trials (CONSORT) guideline 
for pragmatic trials, the Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE) guideline and the International Society for Pharmacoepide-
miology (ISPE) guideline for safety reports. The structure, content, and terminology 
used in the reporting template recommended by the various guidelines were analyzed. 
RESULTS: There were substantial differences in the structure, content and terminol-
ogy recommended by the six guidelines. For example, in contrast to all other guide-
lines, the CONSORT guidelines mention “Objectives” under “Methods” instead of 
“ ‘Introduction.” Under the Results section, for reporting of unadjusted and adjusted 
estimates from outcomes data, the STROBE guideline recommends its inclusion within 
the Main Results section, whereas the CONSORT guideline recommends its inclusion 
within the Outcomes and Estimation section. Some guidelines, especially those focus-
ing on interventional studies, were more similar in content. CONCLUSIONS: Based 
on the evaluation of similarities and differences in the guidelines, we propose a struc-
ture and template for reporting of prospective non-interventional observational 
studies. Recommendations are also provided for adapting the proposed template based 
on study objectives and design.
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ESTIMATING COST-EFFECTIVENESS BASED ON RESULTS OF 
UNCONTROLLED CLINICAL TRIALS: OFATUMUMAB FOR THE 
TREATMENT OF FLUDARABINE- AND ALEMTUZUMAB-REFRACTORY 
CHRONIC LYMPHOCYTIC LEUKEMIA
Batty AJ1, Thompson GJ2, Maroudas PA2, Delea TE3
1BresMed Health Solutions, Shefﬁ eld, UK; 2GlaxoSmithKline, Uxbridge, Middlesex, UK; 3Policy 
Analysis Inc., Brookline, MA, USA
OBJECTIVES: Increasingly, innovative oncology drugs are licensed in settings where 
randomised controlled trials (RCTs) are ethically and/or practically infeasible. The 
